Despite the availability of endoscopic therapy, many patients in the United States undergo surgical resection for non-malignant colorectal polyps. We aimed to quantify and examine trends in the use of surgery for non-malignant colorectal polyps in a nationally representative sample.
US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
Microsoft has partnered with and invested in US-based Adaptive Biotechnologies to map the human immune system genetics using artificial intelligence (AI) for early detection and diagnosis of multiple diseases, including cancer.
Mevion S250i is a compact proton therapy system that has the capacity to deliver conformal radiation therapy treatments with the support of Hyperscan pencil beam scanning technology.
Researchers have developed a new way to magnetise molecules found naturally in the human body, paving the way for a new generation of low-cost magnetic resonance imaging (MRI) technology that would transform our ability to diagnose and treat diseases including cancer, diabetes and dementia.
BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells.
UT Southwestern Medical Center researchers have used precision editing of the bacterial populations in the gut to prevent or reduce the severity of inflammation in a mouse model of colitis.
Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.